Daily Medication Pearl: Vericiguat for Heart Failure

Article

Verquvo is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and heart failure.

Medication Pearl of the Day: Vericiguat (Verquvo)

Vericiguat is a soluble guanylate cyclase (sGC) stimulator indicated to reduce the risk of cardiovascular death and heart failure (HF) emergency department visits following an initial hospitalization for HF or need for outpatient intravenous diuretics in adults with symptomatic chronic HF and ejection fraction less than 45%.

Insight:

  • Dosing: The starting dose of vericiguat is 2.5 mg orally once daily with food.
  • Dosage forms: Tablets: 2.5 mg, 5 mg, and 10 mg.
  • Adverse events: Most common adverse reactions reported in ≥5% are hypotension and anemia.
  • Drug interactions: PDE-5 Inhibitors: Concomitant use is not recommended.
  • Mechanism of action: Vericiguat is a stimulator of sGC, an important enzyme in the nitric oxide (NO) signaling pathway. By directly stimulating sGC, independently of and synergistically with NO, vericiguat augments levels of intracellular cGMP, leading to smooth muscle relaxation and vasodilation.

Sources:

verquvo_pi (merck.com)

verquov image - Google Search

Related Videos
BillionPhotos.com - stock.adobe.com
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim - stock.adobe.com
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
Image credit: Fabio Balbi | stock.adobe.com
Image credit: Melita - stock.adobe.com
Emergency CPR on a Man who has Heart Attack , One Part of the Process Resuscitation (First Aid) - Image credit: Platoo Studio | stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.